Ángel Lanas

Oct 31, 2023 | frontiersin.org | PRADEEP KUMAR |Ángel Lanas

Hepatocellular carcinoma (HCC) represents the third leading cause of cancer-related mortality worldwide (1). Its occurrence is geographically linked to the prevalence of hepatitis B virus (HBV) infection, with incidence rates of 80% in Asia and Africa, while other etiologies (i.e., chronic hepatitis C and alcohol or metabolic-related) are causing an increase in HCC, particularly in developed countries (2).

Oct 30, 2023 | frontiersin.org | Universitat de Barcelona |Departamento de Bioquímica |Facultad de Medicina |Ángel Lanas

Deceased organ donation consists of both donation after circulatory death (CD) and donation after brain death (BD) (1). The majority of liver transplants (~80%) involve organs from BD donors, with 4–20% originating from CD donors (2).

Aug 30, 2023 | frontiersin.org | Ángel Lanas

Inflammatory bowel diseases (IBD) are lifelong and bothersome diseases, with a relapsing-remitting course, including Crohn's Disease (CD) and Ulcerative Colitis (UC) (1, 2). In the Western World the prevalence of IBD is higher and nearly 1% of people will be affected with IBD by 2030. CD is a disabling, destructive and progressive disease in which the inflammation is transmural, commonly affecting the small bowel and potentially involving any portion of the gastrointestinal tract (3).

Jul 10, 2023 | frontiersin.org | Ángel Lanas

The present-day management of chronic hepatitis B virus (HBV) infection depends on persistent monitoring of viral activity, disease progression, and treatment response (1). The goal of therapy for chronic hepatitis B (CHB) is to improve survival by preventing the risk of cirrhosis and end-stage liver disease and to improve quality of life.

Jun 25, 2023 | frontiersin.org | Ángel Lanas

Hepatobiliary and pancreatic cancers, including hepatocellular carcinoma (HCC), gallbladder cancer, cholangiocarcinoma (CCA) and pancreatic ductal adenocarcinoma (PDAC) are lethal malignancies worldwide (1). Despite recent advancements in treatment strategies, the overall survival for patients with hepatobiliary and pancreatic cancers is not essentially improved in past two decades (2, 3).